As the minister indicated, the Patented Medicine Prices Review Board addresses excessive prices, and their findings and actions are matters of public record.
The pan-Canadian Pricing Alliance, which was originated by the provinces and territories, and in which the federal government participates through our drug plans, does negotiate the prices of drugs. For example, they have a framework for the prices of generic drugs as well as specific patented drugs, for which over $3 billion of savings have been achieved to date—